These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26009259)

  • 1. Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer.
    Xu T; Zhu Z; Wang X; Xia L; Zhang X; Zhong S; Sun F; Zhu Y; Shen Z
    Int Urol Nephrol; 2015 Jul; 47(7):1135-41. PubMed ID: 26009259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
    Kluth LA; Xylinas E; Crivelli JJ; Passoni N; Comploj E; Pycha A; Chrystal J; Sun M; Karakiewicz PI; Gontero P; Lotan Y; Chun FK; Fisch M; Scherr DS; Shariat SF
    J Urol; 2013 Aug; 190(2):480-6. PubMed ID: 23376707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.
    Ferro M; Vartolomei MD; Russo GI; Cantiello F; Farhan ARA; Terracciano D; Cimmino A; Di Stasi S; Musi G; Hurle R; Serretta V; Busetto GM; De Berardinis E; Cioffi A; Perdonà S; Borghesi M; Schiavina R; Cozzi G; Almeida GL; Bove P; Lima E; Grimaldi G; Matei DV; Crisan N; Muto M; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Shariat S; Mirone V; Lucarelli G
    World J Urol; 2019 Mar; 37(3):507-514. PubMed ID: 29992381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy.
    da Silva RD; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Chade D; Guglielmetti GB; Pycha A; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Zerbib M; Scherr DS; Shariat SF
    J Urol; 2013 Aug; 190(2):487-92. PubMed ID: 23395802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
    Soave A; John LM; Dahlem R; Minner S; Engel O; Schmidt S; Kluth LA; Fisch M; Rink M
    Urology; 2015 Jul; 86(1):92-8. PubMed ID: 26051839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
    Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
    J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
    Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer.
    Matsumoto A; Nakagawa T; Kanatani A; Ikeda M; Kawai T; Miyakawa J; Taguchi S; Naito A; Otsuka M; Nakanishi Y; Suzuki M; Koga F; Nagase Y; Kondo Y; Okaneya T; Tanaka Y; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
    World J Urol; 2018 Feb; 36(2):249-256. PubMed ID: 29185045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.
    Soria F; Pisano F; Gontero P; Palou J; Joniau S; Serretta V; Larré S; Di Stasi S; van Rhijn B; Witjes JA; Grotenhuis A; Colombo R; Briganti A; Babjuk M; Soukup V; Malmstrom PU; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha E; Ardelt P; Varkarakis J; Bartoletti R; Dalbagni G; Shariat SF; Xylinas E; Karnes RJ; Sylvester R
    World J Urol; 2018 Nov; 36(11):1775-1781. PubMed ID: 30171454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy.
    Mitra AP; Alemozaffar M; Harris BN; Schuckman AK; Skinner EC; Daneshmand S
    Urology; 2014 Dec; 84(6):1420-6. PubMed ID: 25306479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Babjuk M; Bachmann A; Scherr DS; Shariat SF
    Urol Oncol; 2014 Jan; 32(1):49.e7-14. PubMed ID: 24140245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer.
    Dabi Y; Rouscoff Y; Anract J; Delongchamps NB; Sibony M; Saighi D; Zerbib M; Peyraumore M; Xylinas E
    World J Urol; 2017 Feb; 35(2):229-235. PubMed ID: 27272203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of recurrence in non-muscle invasive bladder cancer patients. Do patient characteristics matter?
    Ucpinar B; Erbin A; Ayranci A; Caglar U; Alis D; Basal S; Sarilar O; Akbulut MF
    J BUON; 2019; 24(4):1659-1665. PubMed ID: 31646822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Umeda Y; Yanagawa M; Sugimura Y; Kawamura J
    Int J Urol; 2004 Feb; 11(2):74-82. PubMed ID: 14706010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.